Dermatology News and Research

Latest Dermatology News and Research

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced results of two Phase III studies of its patented Carbamide Peroxide (CPO) solution for the treatment of inflammatory acne vulgaris and rosacea at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

19 Nov 2010

New dressing materials and plasters indicate pathological changes in the skin

Wounds have to be regularly checked, to make sure any complications in the healing process are detected at an early stage. A new material will make it possible to check wounds without changing the dressing: If an infection arises, the material changes its color.

17 Nov 2010

Study finds phenotypic plasticity among melanoma cells

University of Michigan researchers have determined that most types of melanoma cells can form malignant tumors, providing new evidence that the deadliest form of skin cancer does not conform to the increasingly popular cancer stem cell model.

17 Nov 2010

BUSM professor wins 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research

Larry Culpepper, MD, MPH, chair and professor of family medicine at Boston University School of Medicine (BUSM) and chief of family medicine at Boston Medical Center (BMC), is the recipient of the 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research.

16 Nov 2010

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.

16 Nov 2010

Study shows patient-specific factors delay skin cancer treatment

If detected early, nonmelanoma skin cancers (primarily basal cell and squamous cell carcinomas, the two most common forms of skin cancer) can be easily treated. But when left untreated, these skin cancers can grow and even spread, causing considerably more harm than if they were treated upon initial detection. Now, a new study finds that denial is the top reason why patients delay seeking treatment for skin cancer and shows that this delay results in larger, more serious, skin cancers.

15 Nov 2010

Denial is top reason for patients to delay treatment for skin cancer

12 Nov 2010

Childhood asthma risk linked with prenatal paracetamol exposure depends on antioxidant genes in mother

Evidence suggesting that the risk of childhood asthma associated with prenatal paracetamol exposure may depend on antioxidant genes in the mother has been found by a team of UK scientists. The results of their study - which strengthens the argument for a causal link between paracetamol exposure in early life and later childhood asthma - are published online (10 November) in the Journal of Allergy and Clinical Immunology.

11 Nov 2010

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia Therapeutics, Inc. announced today the successful completion of a series of preclinical studies for HYG-102, their lead product for the treatment of vulvar and vaginal atrophy (VVA) and age-related skin fragility. HYG-102 is the lead biodegradable estrogenic candidate in a portfolio of 23 similar compounds licensed from the laboratory of Dr. Richard Hochberg of Yale University.

11 Nov 2010

Restylane boosts people's first impression

A recent study demonstrating that the treatment of nasolabial folds with Restylane positively influences the first impression that an individual projects was published by Dr. Steven Dayan (www.drdayan.com) and DeNova research in the November 2010 issue of Dermatologic Surgery, a leading Dermatology journal. In a study 20 patients received Restylane the popular hyaluronic filler to fill in the nasolabial folds which run from the side of the nose to the side of the mouth.

10 Nov 2010

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.

9 Nov 2010

Apricus receives $733,437 grants under QTDP program

Apricus Biosciences, Inc., today announced the award of three grants totaling $733,437 under the Qualifying Therapeutic Discovery Project program for PrevOnco, RayVa and Femprox which are the Company's development programs in cancer, autoimmune/cardiovascular and female sexual dysfunction, respectively.

8 Nov 2010

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

bitop AG, a biotech company specializing in the development of Ectoin®-containing medical devices, announced the inclusion of the first patient into a clinical trial on the Ectoin inhalation solution in patients with inflammation and airway obstruction.

8 Nov 2010

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented positive preliminary data from fully monitored study data for the entire study population of 80 subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma.

8 Nov 2010

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.

8 Nov 2010

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.

4 Nov 2010

Valeant declares one-time special dividend

Valeant Pharmaceuticals International, Inc. today announced that the Company's Board of Directors (the "Board") has declared a one-time special dividend of US$1.00 per common share (the "Special Dividend") that shareholders of record as of the close of business on November 15, 2010 (the "Record Date") will be entitled to receive on December 22, 2010.

4 Nov 2010

Valeant third quarter revenue decreases 2% to $208.3 million

Valeant Pharmaceuticals International, Inc. announces third quarter financial results for 2010. The merger of Biovail Corporation and Valeant Pharmaceuticals International was completed on September 28, 2010.

4 Nov 2010

Valeant's board approves $1.5 billion securities repurchase program

Valeant Pharmaceuticals International, Inc. today announced that it may make purchases of its convertible notes, senior notes and/or common shares under a $1.5 billion securities repurchase program (collectively, the "Securities Repurchase Program") approved by Valeant's Board of Directors.

4 Nov 2010

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

Lithera, Inc. today announced positive results from a Phase IIb clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.

4 Nov 2010

Dermatology News and Research

Latest Dermatology News and Research

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

New dressing materials and plasters indicate pathological changes in the skin

Study finds phenotypic plasticity among melanoma cells

BUSM professor wins 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

Study shows patient-specific factors delay skin cancer treatment

Denial is top reason for patients to delay treatment for skin cancer

Childhood asthma risk linked with prenatal paracetamol exposure depends on antioxidant genes in mother

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Restylane boosts people's first impression

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Apricus receives $733,437 grants under QTDP program

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Valeant declares one-time special dividend

Valeant third quarter revenue decreases 2% to $208.3 million

Valeant's board approves $1.5 billion securities repurchase program

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dermatology News and Research

Latest Dermatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in